PPARG and inflammatory skin disease: Recent studies using animal models of inflammatory skin diseases have confirmed that topical administration of PPAR-γ ligands like PGZ decreases epidermal hyperplasia, enhances permeability barrier function, and reduces the inflammation mediated by T lymphocytes [61].